Objective: Despite decades of research on risk indicators of spontaneous preterm birth (PTB), reliable biomarkers are still not available to screen or diagnose high-risk pregnancies. Several biomarkers in maternal and fetal compartments have been mechanistically linked to PTB, but none of them are reliable predictors of pregnancy outcome. This systematic review was conducted to synthesize the knowledge on PTB biomarkers identified using multiplex analysis. Materials and methods: Three electronic databases (PubMed, EMBASE and Web of Science) were searched for studies in any language reporting the use of multiplex assays for maternal biomarkers associated with PTB published from January 2005 to March 2014.
Introduction
Preterm birth (PTB; birth before 37 weeks' gestation) is the leading cause of neonatal morbidity and mortality worldwide [1] [2] [3] [4] [5] , yet little is known about its underlying etiology. PTB is a complex syndrome with multifactorial etiologies that can be broadly classified into two groups: (1) spontaneous PTB, which accounts for approximately 70% of the preterm deliveries, and is further referred to, in this review, as PTB; and (2) provider-initiated PTB, also named iatrogenic PTB, which accounts for the remaining 25% of preterm deliveries. The pathways leading to PTB are redundant and overlapping between etiologies; thus, understanding PTB initiators and effectors is difficult, precluding their use as risk predictors for this condition [6, 7] . Development of new technologies and methodological approaches over the past decade has provided an impetus in the search for predictive and diagnostic PTB biomarkers; many of these biomarkers have been identified in maternal-fetal compartments, including maternal blood, amniotic fluid, and cervicovaginal fluids. Still, there is no clear consensus on which biomarker(s) should be considered the best predictor(s) of PTB. The Preterm Birth International Collaborative (PREBIC; www.prebic.org) performed a systematic review of the literature on single maternal biomarkers for PTB [8] . The report identified 116 different biomarkers in 217 studies published in the last four decades. Three other reviews on PTB biomarkers reached similar conclusions, supporting the concept that there are no single biomarkers able to reliably predict PTB [9] [10] [11] . As multiple and intricate pathways result in PTB, it is unlikely that a single biomarker will predict the risk of PTB.
These findings led to additional work by the PREBIC Biomarker Working Group, and a second systematic review examined panels of biomarkers identified through proteomic technologies [12] , specifically through protein electrophoresis and mass spectrometry [matrix-assisted laser desorption/ionization (MALDI) or surface-enhanced laser desorption/ionization (SELDI)] protein profiling. From a total of 64 dysregulated proteins identified, none of them were reproducible or capable of predicting PTB. As observed in single-biomarker studies, the use of technologically different assay platforms and analytical approaches contributed to a lack of reproducible data for identifying reliable PTB biomarkers, as did heterogeneity in study design, sampling, assay methods, and analysis. However, as an unbiased approach, a well-designed proteomic study is still promising to yield novel biomarkers.
Technological advancements in the past decade have further modernized biomarker discovery. Multiplexed assays and quantitative protein microarrays have led to the publication of a large number of biomarker studies related to PTB. Advantages of multiplex technology include simultaneous analysis of a broad panel of biomarkers chosen by investigators based on known biomolecular pathways of preterm labor, use of a small sample volume, cost effectiveness, and minimal technological challenges compared to proteomics [13] . Several reports have been published in the past decade using multiplex platforms to report different PTB-related end phenotypes including intra-amniotic infection and inflammation, histological chorioamnionitis, and early onset neonatal sepsis in PTB [14] [15] [16] [17] [18] [19] [20] . Samples tested included maternal blood, amniotic and cervicovaginal fluid, and umbilical cord blood.
PREBIC conducted this third systematic review to synthesize the knowledge on PTB biomarkers identified using multiplex approaches. We reviewed the literature published in the last decade on studies using multiplex technologies in identification of PTB biomarkers (search limited to biomarkers of spontaneous PTB only) in various biological samples collected from asymptomatic and symptomatic women with PTB and intact membranes.
Methods

Study identification and selection
We sought studies that used multiplex assay techniques to document potential biomarkers associated with PTB published between January 2005 and March 2014. The search was conducted without language restriction in three electronic databases (PubMed, EMBASE and Web of Science) via OVID. All citations identified were downloaded into Mendeley electronic reference software (Mendeley Ltd., London, UK), and duplicates were excluded. Two independent reviewers screened the titles and abstracts of unique citations, and potentially relevant studies were selected for full-text reading; those that fulfilled the selection criteria were included in the review. Discrepancies between the reviewers were discussed until consensus was reached; in case of persistent disagreement, a third reviewer was consulted.
The search was complemented by screening the reference lists of included studies. A search for unpublished studies was not performed. The search strategy used the following terms and synonyms, adapted according to each database: ( 
Type of study
Studies that used any multiplex assay in search of multiple biomarkers for PTB and provided qualitative and/or quantitative information about biomarkers were considered eligible for inclusion. All types of study designs were considered acceptable, including cross-sectional, case-control, case-only, and cohort studies.
Population
Studies enrolling symptomatic or asymptomatic women at high or low risk for PTB of any gestational age < 37 weeks, parity, race, age, or socioeconomic background were eligible for inclusion in the review.
Definition of multiplex assay
Multiplex assay was defined for the purpose of this review as simultaneous detection of more than one analyte in a single biological reaction using a combination of specific antibodies with no documented cross-reactivity but compatible in combined assays.
Types of outcome
The target outcome was spontaneous preterm labor with intact membranes leading to preterm delivery. The comparison groups included either term labor or preterm-matched gestational age.
Exclusion criteria
Studies were excluded if any of the following applied: (1) pregnancies with other associated complications, such as preeclampsia, intrauterine growth restriction, stillbirth, miscarriage, diabetes, abruptio placentae, or preterm premature rupture of membranes; (2) infection or chorioamnionitis associated with PTB; (3) animal-model studies; (4) genetic syndromes or diseases; (5) in vitro studies; (6) gene polymorphisms studies; (7) microbial detection as main objective of the study (microbiologic studies); (8) clinical trials, and (9) multiple pregnancies.
Data extraction
Two independent reviewers extracted data from the eligible studies using a standardized electronic data extraction form prepared for this review. The following data were collected: author; journal; year of publication; country where the study was conducted; study objective and design; total number of participants; number of cases and controls; patient characteristics at baseline including age, race, clinical symptoms, and risk of PTB; outcome phenotype definition; antenatal steroid administration; gestational age at the time of sample collection; source of biological sample; type of multiplex assay; method of validation of the results; and data analysis approach.
Additional relevant assay-related information, such as processing, storage, and dilution of samples, was also collected, if available. The data collected were compared and discussed by the reviewers, and disagreements were resolved by consensus.
Assessment of the quality of the studies
Two independent reviewers assessed the quality of the included studies according to a set of parameters defined for this review using the QUADAS tool [21] and based on our group's previous experience with this type of study [8, 12] . Differences in opinions between reviewers were resolved by consensus; in case of persistent disagreement, a third senior reviewer was consulted.
Grading criteria were as follows:
Grading of population characteristics
Well defined Detailed description of study group(s) (cases, controls), ethics and consent procedure, and inclusion and exclusion criteria. Inclusion criteria should have the definition of phenotype, estimation of gestational age, and gestational age at recruitment and at sample collection. Exclusion criteria should be explained in detail.
Adequately defined Brief description of study groups (cases, controls). Inclusion criteria should have the definition of phenotype, information as to how gestational age was assessed, and gestational age at recruitment and at sample collection. Exclusion criteria should be explained in detail. Poorly described or not reported Difficult to understand study design, study groups, or inclusion and exclusion criteria, and does not provide details listed above.
Grading quality of biomarker sampling
Well defined Detailed description of the sample type, sample collection protocol, timing of sample collection (gestational age), clinical status at sampling (symptomatic vs. asymptomatic), pre-analytical processing of the sample, and storage conditions. Adequately defined Brief description of the sample type, sample collection, and pre-analytical processing of the sample, but some aspects are missing or unclear. Poorly described or not reported Most of the details are missing and/or difficult to understand as to how the sample collection and pre-analytical processing of the sample were performed, mainly regarding storage and dilution.
Grading quality of multiplex analysis
Well defined Detailed description of sample processing and assay. Details included multiplex assay platform and its manufacturer, number of analytes, source of antibodies and their cross-reactivity and compatibility, lower and upper levels of detection, standards used and methods for calculation of observed concentrations, details on assay performance (intra-assay and inter-assay variabilities), and statistical analysis approaches, including control for multiple comparisons.
Adequately defined Brief description of the sample processing, multiplex assay, and analytical details as described above.
Poorly described or not reported Most of the details are missing and/or it is difficult to understand how the samples were prepared and proteomic analyses were performed.
Data synthesis
Biomarkers were grouped according to the name of the identified protein of interest retrieved from the UniProt database, type of sample, and multiplex approach. We planned to pool the results of similar studies in a meta-analysis to assess the results of different multiplex analyses in biological samples from women with and without PTB.
Results
The search of three electronic databases yielded 3631 unique citations, 3598 of which were excluded as irrelevant after title and abstract screening; 33 were selected for full-text reading. From those selected, 22 studies [19, that did not fulfill the selection criteria and one study [26] for which the full text could not be obtained after repeated attempts was excluded. Ten studies that used multiplex assay for identification of PTB biomarkers in maternal and/or fetal samples were included in the review. A process flowchart of study identification, selection, and inclusion is presented in Figure 1 . Main characteristics of the ten studies included in the present review are summarized in Table 1 . These studies were conducted in seven developed countries and published between 2006 and 2013 in North American or European journals of obstetrics and gynecology or immunobiology, reflecting both clinical and basic science readership. There were four cohort studies [15, 20, 44, 46] , five case-controls [14, 16, 17, 43, 45] , and one cross-sectional [18] . Although race/ethnicity plays a major role in biomarker disparity associated with PTB, only two studies reported on the ethnicity of the studied populations [17, 20] . Gestational age (GA) at sample collection, an important factor influencing biomarker association with PTB, was reported in all studies except one [43] ; however, the missing information was obtained for this study through personal communication with the authors (Table 1 ). All studies reported a calculation of GA based on the last menstrual period corroborated by ultrasound dating in the second trimester. In nine out of the ten studies, the samples were collected from patients with symptomatic preterm labor, while in the remaining study, the samples were collected from asymptomatic pregnant women [45] .
Biological samples
Fourteen sets of biological samples were analyzed. Three studies analyzed more than one biological sample [14, 17, 20] . The majority of the samples were maternal blood (57.1%), either plasma or serum, followed by amniotic fluid (14.1%), fetal plasma, placenta, choriondecidua, and cervical fluid (7.2% each). Samples were collected during labor (69.2%), after delivery (18.1%), and, in one prospective cohort, between 24 and 26 weeks of gestation before the Unique citations identified through electronic search n=3631
Citations excluded after screening titles and abstracts n=3598
Citations selected for full-text reading n=33
Studies included in the review n=10
Citations excluded after full-text reading n=23
No multiplex approach (specific immunoassays/mass
Inclusion of PPROM along with PTB
In-vitro study onset of labor [45] . Seventy percent of the studies provided details on sample collection, preparation, and storage. Details about sample size calculation were provided only by one paper [14] . An acceptable power calculation was not provided by any of the studies, likely due to either a lack of prior data for power calculation or the inability to generate power that would be able to detect significant changes in multiple analyte concentrations among various groups. Sample size varied from 30 to 648 participants, with most of the studies (76.9%) including fewer than 100 subjects comprising both cases and controls.
Type of multiplex assays used
The assays used in the selected studies are listed in Table 1 . Forty percent of the studies used multiplexed assays based on Luminex technology (LabMAP, Luminex Corp, Austin, TX, USA) [47, 32, 24, 15] , while FAST Slide protein microarray platform (Whatman Laboratories, Little Chalfont, Buckinghamshire, UK), Meso Scale Discovery (MSD; Gaithersburg, MD, USA), Searchlight assay (Pierce Biotechnology Laboratory, Rockford, IL, USA), and Raybiotech assay (Norcross, GA, USA) were used by Brou et al. [17] , Faupel-Badger et al. [44] , Laudanski et al. [18] , and Laudanski et al. [43] , respectively. Only one study performed validation of the multiplex assay [16] , while the others referenced previous work or provided no details. The rationale for the assay choice was not explicitly provided in any of the studies.
Biomarkers associated with PTB
The panel of biomarkers analyzed between studies varied widely. The number of analytes reported ranged from two [46] to 44 [17] . From the total of 78 different biomarkers analyzed, 42 were associated with PTB ( Table 2 ). The majority of the studied biomarkers were cytokines, chemokines, cytokine agonists or antagonists, receptors and soluble receptors, metalloproteinases and their inhibitors, growth and angiogenic factors, and adhesion molecules known to be involved in inflammatory pathways associated with PTB. Of the 31 PTB-related biomarkers assessed in maternal serum (see Table 1 ), the ones most frequently identified were RANTES [14, 15, 20] and IL-10 [15, 17, 20] followed by MIP-1β, GM-CSF [15, 20] , Eotaxin [17, 43] , and TNF-RI [15, 17] . Increased amniotic fluid ANGPT2 was associated with PTB [17] , and the levels of ICAM-1, IGF-I, IL-1β, IL-1Rα, IL-8, MCP-3, MIP-1α, PDGF-BB, TGF-α, TGF-β1, TIMP1, TNFα, TNFR-I, TNFR-II, and VEGF were Interleukin-18 Holst et al. [20] Tumor necrosis factor
Tumor necrosis factor-α TNF P01375 Fetal plasma, amniotic fluid, cervical fluid Brou et al. [17] , Holst et al. [20] Tumor necrosis factor receptor superfamily member 1 A Tumor necrosis factor receptor 1 TNFRSF1A P19438 Maternal plasma, fetal plasma, maternal plasma Tsiartas et al. [15] , Brou et al. [17] Tumor necrosis factor receptor superfamily member 1B Tumor necrosis factor receptor 2 TNFRSF1B P20333 Fetal plasma Brou et al. [17] Tumor necrosis factor ligand superfamily member 6
Fas-ligand
Brou et al. [17] Vascular endothelial growth factor A Vascular endothelial growth factor A VEGFA P15692 Fetal plasma Brou et al. [17] higher in fetal plasma from PTB cases than in fetal plasma from term delivery controls [17] . RANTES [14, 15, 20] and IL-10 [15, 17, 20] were found to associate with PTB by three studies. These articles were further analyzed for pooling their results in a metaanalysis. However, we could not perform a meta-analysis because of major differences in the biological samples and study populations. Tsiartas et al. [15] and Holst et al. [20] used the same biomarker panel (27-plex) , and the assays were performed by the same laboratory. Both studies reported an association between RANTES in various biological compartments and latency in the onset of preterm labor. Holst et al. [20] reported that RANTES levels in the amniotic and cervical fluids were significantly associated with delivery within 7 days, while Tsiartas et al. [15] found that high levels of maternal serum RANTES and short cervical length were significant to the prediction of spontaneous preterm delivery within 7 days. In the third work, Hamilton et al. [14] reported that RANTES increased in plasma from preterm in-labor women compared to preterm but not in labor; however, no differences were reported between PTB and normal term birth samples. Similarly, there were differences in the types of samples and phenotypes of the outcomes reported by the three studies that measured IL-10 [15, 17, 20] , which also prevented us from pooling the results into a meta-analysis. In a retrospective cohort study, Brou et al. [17] reported decreased IL-10 in maternal plasma in PTB compared to normal term births. Tsiartas et al. [15] found higher maternal serum IL-10, whereas Holst et al. [20] reported an increase in both cervical and amniotic fluids IL-10 associated with delivery within 7 days in women with PTB compared to those women who did not deliver within 7 days.
A complete list of the biomarkers, frequency of testing, and the distribution according to the pathophysiologic pathway is provided in Table 1 .
Quality assessment
As shown in Figure 2 , most of the studies included in the review (8/10) had a well-defined study population [15-18, 20, 46, 44, 45] . Only two studies received a low-quality grading because of poor description of the characteristics of the sample population [14, 43] . In five articles, the sample collection and preparation were well described [15, 17, 18, 20, 45] . Sample collection and management were adequate in four other studies [16, 46, 44, 43] , and one article provided only a summary description [14] . The assay methodology was well defined in five studies [15, 17, 18, 20, 45] , whereas two studies [16, 46] were graded of adequate quality, and three were judged to be of poor quality [14, 43, 44] .
Discussion
PTB is a complex syndrome characterized by pathways with interacting biomarkers [47, 48] . In this review, we examined multiplex assays where multiple biomarkers were studied simultaneously in the same sample. We identified ten eligible studies that analyzed 74 biomarkers and identified 42 dysregulated biomarkers associated with PTB. Most of these studies recruited European-American and African-American populations. Several biomarkers were found to be associated with PTB in maternal plasma/ serum samples in more than one study, and RANTES and IL-10 emerged as potential candidates for further evaluation and validation studies with similar methodological approaches. However, criteria for performing a meta-analysis were not met, as none of the biomarkers were replicated in additional samples/studies by the same investigators or by other investigators following the same approach, population, and outcome. We have chosen not to discuss biomarkers reported in tissue-based studies as their usefulness in predicting PTB in clinical specimens has yet to be evaluated. Accordingly, this systematic review also concludes that, at present and based on reported findings, no single or combination of biomarkers can be used to predict PTB risk.
Unlike the findings from our two previous systematic reviews [8, 12] , the multiplex studies included in this review had an overall better design and quality of reporting. Most of these studies were published fairly recently (between 2006 and 2013), and it is encouraging that a follow-up or replication study can be performed easily as the limitations are fewer and easier to address. However, many of the methodological issues reported in the aforementioned prior reviews still persist, especially with respect to study design, hindering PTB biomarker discovery. We highlight below some of these concerns. All reports included in this review defined the studied outcome phenotype as spontaneous PTB. However, definition of this phenotype still remains as an enigma in PTB research due to the lack of standard and established definitions used in biomarker discovery and clinical trials. Recent reports highlighted the urgent need for defining PTB phenotypes [7, 49, 50] . A gold standard is yet to be developed, and investigators are still using their own criteria for phenotype definition.
One key area identified by this report is the heterogeneity in the selection of biomarkers. Two major criteria used by investigators in biomarker panel selection led to a high diversity of biomarkers evaluated in a relatively small number of studies: (1) investigation of a specific pathophysiologic pathway of PTB and (2) convenience in using a predefined assay. Just like any other "candidate" marker studies, bias is introduced when selecting the panel by either of these methods. Although there are no proper solutions for eliminating bias in candidate marker selection, incorporating biomarkers from all known and reported pathways, rather than skewing the selection of markers by choosing from "desired" pathways, is not the best approach to minimize such biases. Selection of panels based on convenience and without proper rationale or biological relevance is unlikely to yield reproducible data.
Multiplex assays have emerged as important tools for screening disease-related biomarkers. Numerous types of multiplex arrays are available on the market from different manufacturers, differing by number and type of cytokines included in the array, sensitivity in detection, the variety of antibodies and standards used in the kits, and incubation time [51] . In our review, 40% of the studies used the Luminex technology assay (LabMAP) [52] . Using a multiplex bead array, Luminex assays facilitate simultaneous cytometric quantitation of multiple immune mediators (i.e. cytokines) in solution by capturing these to spectrally distinct beads with the distinct advantages of higher throughput, smaller volume (as little as 12 μL per sample) of various biological samples (e.g. maternal serum, cervical or vaginal fluid), and lower costs [53] . However, one of the included studies applied the FAST Slide protein microarray platform [17] . The main advantage of this technology is that the matrix retains arrayed proteins in a near-quantitative fashion that translates into antibody arrays with sensitivity down to antigen concentrations of 1 pg/mL. Faupel-Badger et al. [44] used MSD multiplex microarray, which is based on MULTI-ARRAY ® technology, a proprietary combination of electrochemiluminescence detection and patterned arrays. The instrument (Sector Imager 2400) that is used to detect signals from the assay uses highly efficient custom-designed optics and ultrasensitive photo detectors to collect and quantitatively measure light emitted from the microplates. In 2006, Laudanski et al. [18] used a Searchlight assay which is a multiplexed sandwich enzyme-linked immunosorbent assays (ELISAs) with imaging system based on a cooled charge-coupled device camera which detects the chemiluminescent signal at each spot in the array. In 2012, Laudanski et al. [43] used a multiplex-based platform from Raybiotech for simultaneous quantitative measurement of different proteins from one sample, which has the advantage of being read by most of the conventional array fluorescent plate readers available on the market. Considering the diversity in described assays, it appears that the choice in using one particular assay may be driven by several decision factors, such as a researcher's familiarity with a specific PTB pathway, a particular research question, the type of biological sample available, convenience, and financial feasibility.
Other areas of heterogeneity among studies included study design, type of sample used for biomarker discovery, timing of sample collection, and inclusion of asymptomatic or symptomatic women. The methodology of statistical analysis employed introduced yet another field of heterogeneity. Many of these studies lacked reporting on confounding variables and control for multitudes of covariates. Therefore, results may also have been impacted by association by chance due to analysis confounded by multiple testing or lack of adequate power. Many of these issues were identified and discussed in detail in our prior systematic reviews. Readers are encouraged to review the guidelines and checklists in our previous publications that apply to studies using multiplex assays [8, 12] . Moreover, based on the above-detailed issues in identifying PTB biomarkers through multiplex approaches, we suggest a few guidelines to consider prior to initiation of future studies.
Suggested approaches for multiplex assay discovery and future validation strategies
Success of a biomarker study is directly dependent on the quality of specimen collection and how it is processed until assay, considering appropriate preservatives and storage conditions to avoid any variations in the biomarker level and integrity. Reporting should include a detailed description of these procedures, as well as sensitivity and specificity of the assay, and inter-and intra-assay variations should be considered and reported. Sampling is dependent upon study design and other rationale established prior to collecting, and biological specimens that are easy to obtain should be chosen to assess the risk of PTB. The appropriate sample size of required cases and controls should be calculated to properly evaluate the association of biomarkers alone and in combination, and this parameter depends on the number of analytes under investigation. Thus, sample size calculations for exploratory factor analysis should be employed. While no optimal cases-to-controls ratio exists, a higher ratio of controls to cases would result in greater study power. Subjectto-variable ratios from 20:1 to 100:1 are not uncommon. When the number of biomarkers is large compared to the number of cases and controls, chance associations may be uncovered and hinder progress. Statistical analysis and proper selection of analytical methods should address the hypothesis and objectives established prior to the study and the study design. We recommend the following steps: (1) perform statistical assessment of distribution of biomarker concentration (normal or non-normal); (2) select appropriate form of presenting data based on distribution [i.e. mean±standard deviation (SD), median (interquartile range)]; (3) identify potential confounding factors (e.g. clinical and demographic) and adjust for confounders; and (4) adjust for multiple testing. If the discovery set has sufficient power to project biomarker combinations, the interference on quantitation should be evaluated as well. For example, if the discovery multiplex assay evaluated a large number of potential markers and the results indicate that only a small number are associated with PTB risk, it might make sense to only test the smaller number in future validation efforts. In this context, a prospective validation using a new, independent set of specimens is also required to confirm the performance of the biomarker panel. During this validation, it is not appropriate to add additional biomarkers or adjust the predictive algorithm; if such modifications are required to improve the prediction, then a new prospective effort utilizing an independent specimen set is required to validate the modifications.
The mathematical algorithm, which combines the assay results of each biomarker into a single output predictive of PTB, is as important as the biomarkers of a predictive biomarker combination. Prior to the validation studies using this algorithm, a sample set independent of those used in discovery phase can be tested for the optimization of the algorithm. Indeed, even if the biomarker set includes numerous proteins, these measurements should be combined into a single risk estimate (similar to combination of multiple markers to provide a single estimate for the risk of other diseases). Multi-marker assays developed in this way are amenable to traditional validation methods.
The rationale behind biomarker research assumes that multiple biomarkers perform better than a single biomarker for assessing PTB risk. Success of biomarker studies depends on the ability to identify those biomarkers that predict PTB from within the larger panel of biomarkers studied. These biomarker sets may be difficult to identify unless statistical approaches allow for the possibility that each biomarker of the set is by itself a poor predictor, and perform well only in combination. Negative results of studies to date could have been hindered by a lack of this type of analysis.
Finally, appropriate reporting of data involves following all the listed guidelines throughout the study. Reporting should be based on the hypothesis tested and match the studied objectives. Inclusion of study limitations will help the reader better interpret reported findings and address such limitations in future studies.
In summary, multiplex assays provide promising technological advancement in identifying biomarkers of PTB over other approaches that our group has previously systematically reviewed. Understanding the limitations of existing reports and designing studies, following the criteria detailed above may facilitate the identification of better biomarkers for screening and prediction of PTB.
